Effects of riluzole on clinical evolution and survival of patients with amyotrophic lateral sclerosis in Costa Rica
DOI:
https://doi.org/10.51481/amc.v57i4.898Keywords:
amyotrophic lateral sclerosis, survival, riluzole, Costa RicaAbstract
Background and aim: There is no study on the use of riluzol in patients with amyotrophic lateral sclerosis in Costa Rica. The objective of this study was to assess the impact of riluzole on clinical evolution and survival of patients with amyotrophic lateral sclerosis treated at the National Pain Control and Palliative Care Center.
Materials and methods: An analytical, observational and retrospective study based on the records of patients with amyotrophic lateral sclerosis treated at the National Pain Control and Palliative Care Center between January 2009 and May 2014. The statistical analysis was performed using Microsoft Excel and SPSS version 18. Kaplan - Meier estimates were used for the analysis of survival estimates and a survival analysis was performed using a multivariate Cox regression.Results: We analyzed 235 medical records of patients diagnosed with ALS being controlled at the National Pain Control and Palliative Care Center, of which 142 (60%) were treated with riluzole and 93 (40%) did not take this drug, for a ratio of 1.5; 66% were men and 34% women. Patients treated with riluzole showed a median survival of 25.0 months (95% CI 19.8 to 30.5 months) and patients which didn t receive treatment with riluzole showed a median survival of 18.0 months (95% CI 7.8 to 28.2 months), with a p-value of 0.17 for the comparison of survival distributions. In addition, a statistically significant difference in the time between the beginning of treatment with riluzole and placement of PEG (p-value 0.001) was found. Patients that received riluzole showed an increased average time before requiring the placement of PEG.
Conclusions: Patients using riluzole showed an increase in survival of seven months compared with those who didn t(p = 0.17). Also, we observed that patients taking the drug presented a delay in requiring the placement of the percutaneous endoscopic gastrostomy.
Downloads
References
Miller R, Mitchell J, Lyon M, Moore D. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007; 24:1-28.
Pérez A, Vanegas E. Evaluación de efectividad y seguridad del riluzol como tratamiento para prolongar el tiempo libre de traqueostomia en pacientes con esclerosis lateral amiotrófica. Instituto de Evaluación Tecnológica en Salud. Colombia, 2013. Recuperado el: 01 de agosto del 2015. En:http://www. iets.org.co/reportes-iets/Documentacin%20Reportes/Esclerosis%20 lateral% 20amiotrófica%20(riluzol).pdf
Granados A, Torres G, Pardo R. Esclerosis lateral amiotrófica. Una revisión crítica sobre su tratamiento con riluzole. Acta Neurol Colomb 2007; 23:33-40.
Vásquez M, Eimil M, Arroyo R. Esclerosis lateral amiotrófica: pronóstico y tratamiento. JANO 2005; 1579:49-53.
Domenico G. Esclerosis lateral amiotrófica. En: Declan Walsh, ed. Medicina Paliativa. EES, 2010: 1062-1067.
Rodríguez-Paniagua P, Salas-Herrera I, Cartín-Brenes M. Incidencia de esclerosis lateral amiotrófica en Costa Rica. Acta méd costarric 2007; 49:33-37.
Piemonte and Valle d´Aosta Register for Amyotrophic Lateral Sclerosis (PARALS). Incidence of ALS in Italy: Evidence for a uniform frequency in Western countries. Neurology 2001; 56:239-244.
Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995-1997: a population-based study. Neurology 1999; 52:504-509.
Bellingham M. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther 2011; 17:4-31.
Martí-Fabregas J, Pradas J. Esclerosis lateral amiotrófica. Neurología 1996; 11:99-103.
Martínez J. Riluzol: Revisión, consejos y puntos prácticos en el tratamiento de la esclerosis lateral amiotrófica. Acta Neurol Colomb 2007; 23:28-32.
Rilutek® (Riluzol). Monografía del producto. Rhȃne-Poulenc Rorer S.A, Francia 1996.
Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330:585-591.
Lacomblez L, Bensimon G, Leigh P, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/ Riluzole Study Group II. Lancet 1996; 347: 1425-1431.
Calzada-Sierra D, Gómez-Fernánderz L. Importancia del tratamiento rehabilitador multifactorial en la esclerosis lateral amiotrófica. Rev Neurol 2001; 32:423-426.
Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research. J Neurol Sci 1999; 169:2-12.
Marín J. Esclerosis lateral amiotrófica: una actualización. Rev Mex Neuroci 2009; 10: 281-286.
Orient-Lóper F, Terré-Boliart R, Guevara-Espinosa D, Bernabeu-Guitart M. Tratamiento neurorehabilitador de la esclerosis lateral amiotrófica. Rev Neurol 2006; 43:549-555.
Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64:380-382.
Howard R, Orell R. Management of motor neuron disease. Postgrad Med J 2002; 78:736-741.
Downloads
Published
Versions
- 2015-10-19 (2)
- 2015-10-19 (1)
Issue
Section
License
Copyright (c) 2015 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
